CEL-SCI Corp
CVM8.670USD
-0.250-2.80%
Fechamento 09/19, 16:00（ET）Cotações atrasadas em 15 min
46.14MValor de mercado
PerdaP/L TTM
Mais detalhes de CEL-SCI Corp Empresa
CEL-SCI Corporation is a late clinical-stage biotechnology company. It is engaged in research and development directed at improving the treatment of cancer and other diseases by using the immune system, the body’s natural defense system. It is focused on the development of product candidates and technologies, including Multikine and Ligand Epitope Antigen Presentation System technology (LEAPS). Multikine (Leukocyte Interleukin, Injection), a true first-line cancer therapy, which is designed to help the immune system target the tumor at a time when the immune system is still relatively intact and thereby thought to be better able to mount an attack on the tumor. LEAPS is designed to stimulate the human immune system to more effectively fight bacterial, viral and parasitic infections as well as autoimmune conditions, allergies, transplantation rejection and cancer, when it cannot do so on its own. The LEAPS candidates include CEL-2000, CEL-4000 and DerG-PG275(Cit) (aka, CEL-5000).
Informações da empresa
Código da empresaCVM
Nome da EmpresaCEL-SCI Corp
Data de listagemDec 08, 1983
CEOMr. Geert R. Kersten, Esq.
Número de funcionários- -
Tipo de títulosOrdinary Share
Fim do ano fiscalDec 08
EndereçoSuite 802
CidadeVIENNA
Bolsa de valoresNYSE American Consolidated
PaísUnited States of America
Código postal22182
Telefone17035069460
Sitehttps://cel-sci.com/
Código da empresaCVM
Data de listagemDec 08, 1983
CEOMr. Geert R. Kersten, Esq.
Executivos da empresa
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Geert R. Kersten, Esq.
Mr. Geert R. Kersten, Esq.
Chief Executive Officer, Chief Financial Officer, Treasurer, Director
Chief Executive Officer, Chief Financial Officer, Treasurer, Director
72.83K
+66.91%
Ms. Patricia B. Prichep
Ms. Patricia B. Prichep
Co-Chief Financial Officer, Chief Operating Officer, Corporate Secretary
Co-Chief Financial Officer, Chief Operating Officer, Corporate Secretary
10.75K
+21.11%
Dr. Eyal Talor, Ph.D.
Dr. Eyal Talor, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
5.55K
+23.29%
Mr. Robert Eugene (Bob) Watson
Mr. Robert Eugene (Bob) Watson
Independent Chairman of the Board
Independent Chairman of the Board
3.73K
+358.60%
Mr. Bruno Jean-Marie Baillavoine
Mr. Bruno Jean-Marie Baillavoine
Independent Director
Independent Director
199.00
--
Mr. John Cipriano
Mr. John Cipriano
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Mr. Mario Gobbo, Ph.D.
Mr. Mario Gobbo, Ph.D.
Independent Director
Independent Director
--
--
Dr. Daniel H. Zimmerman, Ph.D.
Dr. Daniel H. Zimmerman, Ph.D.
Senior Vice President - Research, Cellular Immunology
Senior Vice President - Research, Cellular Immunology
--
--
Nome
Nome/Posição
Posição
Ações detidas
Variação
Mr. Geert R. Kersten, Esq.
Mr. Geert R. Kersten, Esq.
Chief Executive Officer, Chief Financial Officer, Treasurer, Director
Chief Executive Officer, Chief Financial Officer, Treasurer, Director
72.83K
+66.91%
Ms. Patricia B. Prichep
Ms. Patricia B. Prichep
Co-Chief Financial Officer, Chief Operating Officer, Corporate Secretary
Co-Chief Financial Officer, Chief Operating Officer, Corporate Secretary
10.75K
+21.11%
Dr. Eyal Talor, Ph.D.
Dr. Eyal Talor, Ph.D.
Chief Scientific Officer
Chief Scientific Officer
5.55K
+23.29%
Mr. Robert Eugene (Bob) Watson
Mr. Robert Eugene (Bob) Watson
Independent Chairman of the Board
Independent Chairman of the Board
3.73K
+358.60%
Mr. Bruno Jean-Marie Baillavoine
Mr. Bruno Jean-Marie Baillavoine
Independent Director
Independent Director
199.00
--
Mr. John Cipriano
Mr. John Cipriano
Senior Vice President - Regulatory Affairs
Senior Vice President - Regulatory Affairs
--
--
Detalhamento da receita
Sem dados
Sem dados
Por Empresa
Por Região
Sem dados
Distribuição de ações
Atualizado em: qua, 3 de set
Atualizado em: qua, 3 de set
Investidores
Tipos de investidores
Investidores
Investidores
Proporção
Lincoln Alternative Strategies LLC
6.94%
The Vanguard Group, Inc.
2.29%
BlackRock Institutional Trust Company, N.A.
1.43%
Kersten (Geert R)
0.91%
MAI Capital Management, LLC
0.81%
Outro
87.61%
Investidores
Investidores
Proporção
Lincoln Alternative Strategies LLC
6.94%
The Vanguard Group, Inc.
2.29%
BlackRock Institutional Trust Company, N.A.
1.43%
Kersten (Geert R)
0.91%
MAI Capital Management, LLC
0.81%
Outro
87.61%
Tipos de investidores
Investidores
Proporção
Corporation
6.94%
Investment Advisor
4.50%
Individual Investor
1.24%
Investment Advisor/Hedge Fund
1.14%
Research Firm
0.54%
Outro
85.64%
Participação acionária institucional
Atualizado em: ter, 1 de jul
Atualizado em: ter, 1 de jul
Período do relatório
N.º de instituições
Ações detidas
Proporção
Variação
2025Q2
130
280.62K
4.34%
-122.18K
2025Q1
141
362.72K
6.33%
+7.45K
2024Q4
154
8.90M
11.54%
-654.04K
2024Q3
159
7.92M
12.84%
-1.82M
2024Q2
170
8.27M
15.20%
-2.00M
2024Q1
223
9.54M
17.62%
-953.00K
2023Q4
231
8.54M
17.00%
-1.14M
2023Q3
241
7.38M
15.57%
-2.53M
2023Q2
252
7.44M
15.71%
-2.96M
2023Q1
267
7.49M
17.10%
-3.36M
Ver Mais
Atividade dos acionistas
Nome
Ações detidas
Proporção
Variação
Var. %
Data
The Vanguard Group, Inc.
78.44K
1.53%
-584.00
-0.74%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
26.09K
0.51%
-83.00
-0.32%
Mar 31, 2025
Kersten (Geert R)
43.64K
0.85%
+2.29K
+5.54%
Jun 30, 2025
MAI Capital Management, LLC
17.55K
0.34%
+12.23K
+229.87%
Mar 31, 2025
UBS Financial Services, Inc.
2.94K
0.06%
+18.00
+0.62%
Mar 31, 2025
Geode Capital Management, L.L.C.
25.10K
0.49%
+6.01K
+31.51%
Mar 31, 2025
Osaic Holdings, Inc.
9.64K
0.19%
-4.40K
-31.36%
Mar 31, 2025
Prichep (Patricia B)
10.75K
0.21%
+1.87K
+21.11%
Jun 30, 2025
Ver Mais
ETFs Relacionados
Nome
Proporção
Sem dados
Dividendo
Um total de
0.00
USD foi distribuído em dividendos nos últimos 5 anos.
Data
Dividendo
Data de registro
Data de pagamento
Data ex-dividendo
Sem dados
Desdobramento de ações
Data
Tipo
Proporção
Sem dados
Data
Tipo
Proporção
Sem dados
